New York-based Ophthotech Corp. saw its shares plummet 86.4 percent in heavy trading Monday on news that the pre-specified primary endpoint of mean change in visual acuity at 12 months, measured as best corrected visual acuity (BCVA) in terms of additional letter gains, was not achieved in its two pivotal phase III trials investigating the superiority of Fovista (pegpleranib) anti-platelet-derived growth factor (PDGF) therapy in combination with Lucentis (ranibizumab) anti-VEGF therapy compared to Lucentis monotherapy for the treatment of wet age-related macular degeneration (AMD).